JP2017526696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526696A5 JP2017526696A5 JP2017512683A JP2017512683A JP2017526696A5 JP 2017526696 A5 JP2017526696 A5 JP 2017526696A5 JP 2017512683 A JP2017512683 A JP 2017512683A JP 2017512683 A JP2017512683 A JP 2017512683A JP 2017526696 A5 JP2017526696 A5 JP 2017526696A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- alkyl
- heterocyclyl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JRSIQYMBIOYIKI-CMPLNLGQSA-N CC(C)N[C@@H](C)[C@H](c1c[n](C)nc1)N(C)C Chemical compound CC(C)N[C@@H](C)[C@H](c1c[n](C)nc1)N(C)C JRSIQYMBIOYIKI-CMPLNLGQSA-N 0.000 description 1
- ZVAIRWNDOBFCGA-UHFFFAOYSA-N CNCC(c1ccccc1Cl)N(C)C Chemical compound CNCC(c1ccccc1Cl)N(C)C ZVAIRWNDOBFCGA-UHFFFAOYSA-N 0.000 description 1
- YLYKWCBMDLKEJG-UHFFFAOYSA-N CNCCN(C)CCOC Chemical compound CNCCN(C)CCOC YLYKWCBMDLKEJG-UHFFFAOYSA-N 0.000 description 1
- GYGYDOOXVKDZCF-UHFFFAOYSA-N CNCCN1CCCC1 Chemical compound CNCCN1CCCC1 GYGYDOOXVKDZCF-UHFFFAOYSA-N 0.000 description 1
- KCAUHAHOMIRXAN-UHFFFAOYSA-N CNCCN1CCCCC1 Chemical compound CNCCN1CCCCC1 KCAUHAHOMIRXAN-UHFFFAOYSA-N 0.000 description 1
- FIHCABIMANEXHV-UHFFFAOYSA-N CNNCC(c1ccccc1F)N(C)C Chemical compound CNNCC(c1ccccc1F)N(C)C FIHCABIMANEXHV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046756P | 2014-09-05 | 2014-09-05 | |
| US62/046,756 | 2014-09-05 | ||
| PCT/US2015/048354 WO2016036954A1 (en) | 2014-09-05 | 2015-09-03 | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526696A JP2017526696A (ja) | 2017-09-14 |
| JP2017526696A5 true JP2017526696A5 (enExample) | 2018-10-11 |
| JP6767969B2 JP6767969B2 (ja) | 2020-10-14 |
Family
ID=54266610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512683A Expired - Fee Related JP6767969B2 (ja) | 2014-09-05 | 2015-09-03 | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10155764B2 (enExample) |
| EP (1) | EP3189049B1 (enExample) |
| JP (1) | JP6767969B2 (enExample) |
| CN (1) | CN107074824B (enExample) |
| WO (1) | WO2016036954A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3189046B1 (en) | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| JP6598286B2 (ja) * | 2014-12-05 | 2019-10-30 | 国立大学法人東京工業大学 | チロシンの修飾方法 |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| CN108196068B (zh) * | 2018-01-29 | 2019-09-10 | 武汉大学 | 血管紧张素转化酶启动子区组蛋白乙酰化在制备改善胎源性成年骨质疏松症药物中的应用 |
| KR102085758B1 (ko) * | 2019-08-05 | 2020-03-06 | 연세대학교 산학협력단 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| WO2022026465A1 (en) * | 2020-07-28 | 2022-02-03 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| US12286431B2 (en) | 2020-09-11 | 2025-04-29 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| TWI880049B (zh) * | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022170952A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州阿尔脉生物科技有限公司 | 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途 |
| EP4346815A4 (en) * | 2021-05-27 | 2025-04-02 | Schrödinger, Inc. | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| AU2023333181A1 (en) | 2022-09-02 | 2025-03-13 | Auron Therapeutics, Inc. | Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders |
| CN119236072A (zh) * | 2024-08-21 | 2025-01-03 | 苏州大学 | 一种抑制Acetyl-CoA或乙酰化酶GCN5的试剂及其应用 |
| CN119504796B (zh) * | 2024-11-20 | 2026-03-10 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB808636A (en) * | 1955-08-02 | 1959-02-11 | Cassella Farbwerke Mainkur Ag | Basically substituted heterocyclic compounds |
| JPS4931683A (enExample) * | 1972-07-27 | 1974-03-22 | ||
| FR2707294B1 (fr) | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| CA2456985A1 (en) * | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
| US7897607B2 (en) * | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| JP4852540B2 (ja) * | 2004-06-30 | 2012-01-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのフタラジン誘導体 |
| EP2576520A1 (en) | 2010-05-28 | 2013-04-10 | GE Healthcare UK Limited | Radiolabeled compounds and methods thereof |
| KR101422725B1 (ko) * | 2011-10-19 | 2014-07-25 | 한국화학연구원 | 신규한 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 ｍｃｈ 수용체-1 관련 질환의 예방 또는 치료용 약학적 조성물 |
| UY35103A (es) * | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| US9200005B2 (en) * | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| CN105050595A (zh) | 2013-03-15 | 2015-11-11 | 基因泰克公司 | 通过抑制含布罗莫结构域蛋白brd7和brd9治疗th2介导的疾病 |
| EP3189046B1 (en) | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
-
2015
- 2015-09-03 CN CN201580059719.5A patent/CN107074824B/zh not_active Expired - Fee Related
- 2015-09-03 WO PCT/US2015/048354 patent/WO2016036954A1/en not_active Ceased
- 2015-09-03 EP EP15777756.6A patent/EP3189049B1/en active Active
- 2015-09-03 JP JP2017512683A patent/JP6767969B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-03 US US15/449,692 patent/US10155764B2/en active Active